October 3-4, 2019 | Saguaro Scottsdale | Scottsdale, AZ
www.cbinet.com/VBO
With the rapid influx of new oncology drugs and innovative treatments entering the market, there is a greater urgency to examine the impact of payer-provider payment reform on overall oncology costs and patient outcomes. Now in its 14th year, 14th Annual Value-Based Oncology Management Summit convenes payers, providers, PBMs, manufacturers and specialty pharmacies to discuss current trends, challenges and best practices to bend the oncology cost curve, enhance the quality of care and improve patient outcomes.
Visit www.cbinet.com/VBO for more information. Drug Channels readers will save $300 off the standard registration rate when they use promo code NMT596*.
JOIN VALUE-BASED ONCOLOGY LEADERS TO:
- Assess the current success of alternative oncology payment models
- Understand key components of provider readiness to accept risk in value-based contracts
- Evaluate how shifting payment models, payer initiatives to promote palliative care and advanced care directives impact patient outcomes and total cost of care
- Examine the role of treatment innovation, biosimilars and care-delivery improvement in managing oncology costs
- Explore critical factors, both clinical and financial, affecting the adoption of biosimilars
- Consider the potential impact of the increase in risk-based models on patient access, outcomes and costs
- Discuss the evolving role of specialty pharmacy in filling gaps in the patient cancer care continuum
- Prepare for a mandatory alternative payment model for radiation oncology — Explore the impact of the mandatory model on practices and patient outcomes
- Address how to manage the business of oncology as risk-based reimbursement models increase
- Review the current state of data interoperability within cancer care and consider the benefits of greater access for regulators, health systems, health plans and patients
- Arif H. Kamal, M.D., MBA, MHS, FASCO, Associate Professor of Medicine and Business Administration, Duke University
- Terrill Jordan, President, CEO and Board Member, Regional Care Cancer Associates, LLC
- Jonathan Harding, M.D., Senior Medical Director, Senior Products Division, Tufts Health Plan
- Steven Peskin, Executive Medical Director, Population Health, Horizon Blue Cross Blue Shield of New Jersey
- Anne Hubbard, MBA, Director of Health Policy, The American Society for Radiation Oncology
- Anthony V. Coletta, M.D., MBA, CEO and Chairman of the Board, Tandigm Health a wholly owned subsidiary of Independence Blue
- Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, Director, Pharmacy Cancer Care, Assistant Professor of Pharmacy, Mayo Clinic
- Nick Calla, Vice President, Pharma Relations, BioMatrix Specialty Pharmacy
- And more!
Visit www.cbinet.com/VBO for more information. Drug Channels readers will save $300 off the standard registration rate when they use code NMT596*.
*Offer applies to standard rates only and may not be combined with other offers, category rates, promotions or applied to an existing registration. Offer not valid on workshop only or academic/non-profit registrations.
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.
No comments:
Post a Comment